scholarly journals Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africa—The IeDEA Southern Africa Collaboration

2011 ◽  
Vol 56 (3) ◽  
pp. 270-278 ◽  
Author(s):  
Mary-Ann Davies ◽  
Harry Moultrie ◽  
Brian Eley ◽  
Helena Rabie ◽  
Gilles Van Cutsem ◽  
...  
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
Southern Africa ◽  
Virologic Failure ◽  
Second Line ◽  
Second Line Antiretroviral Therapy

scholarly journals Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa

PLoS ONE ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. e32144 ◽  
Author(s):  
Julie H. Levison ◽  
Catherine Orrell ◽  
Sébastien Gallien ◽  
Daniel R. Kuritzkes ◽  
Naishin Fu ◽  
...  
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
Protease Inhibitor ◽  
Treatment Program ◽  
Virologic Failure ◽  
Hiv Treatment ◽  
Second Line ◽  
Second Line Antiretroviral Therapy

scholarly journals Resistance in Pediatric Patients Experiencing Virologic Failure With First-line and Second-line Antiretroviral Therapy

2013 ◽  
Vol 32 (6) ◽  
pp. 644-647 ◽  
Author(s):  
Catherine Orrell ◽  
Julie Levison ◽  
Andrea Ciaranello ◽  
Linda-Gail Bekker ◽  
Daniel R. Kuritzkes ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Pediatric Patients ◽  
Virologic Failure ◽  
Second Line ◽  
First Line ◽  
Second Line Antiretroviral Therapy

Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa

2016 ◽  
Vol 21 (9) ◽  
pp. 1131-1137 ◽  
Author(s):  
Matthew P. Fox ◽  
Rebecca Berhanu ◽  
Kim Steegen ◽  
Cindy Firnhaber ◽  
Prudence Ive ◽  
...  
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
Second Line ◽  
Adherence Counselling ◽  
Second Line Antiretroviral Therapy

scholarly journals Estimated use of abacavir among adults and children enrolled in public sector antiretroviral therapy programmes in Gauteng, South Africa

2012 ◽  
Vol 13 (3) ◽  
pp. 134-137 ◽  
Author(s):  
D Evans ◽  
M Maskwe ◽  
C Heneger ◽  
I Sanne
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
Public Sector ◽  
Treatment Guidelines ◽  
Hiv Positive ◽  
Second Line ◽  
Gauteng Province ◽  
Paediatric Patients ◽  
Adults And Children ◽  
Second Line Antiretroviral Therapy

In South Africa, abacavir (ABC) is currently recommended as part of first- and second-line antiretroviral therapy (ART) for HIV-positive paediatric patients. Concerns about overprescribing of the drug, particularly to adults, led to an analysis of ABC use in public sector ART programmes. We investigated current prescription of the drug to adults and children accessing ART in 4 public sector programmes across Gauteng Province, South Africa. ABC was almost exclusively prescribed to children initiating ART and adults requiring regimen changes due to drug toxicities. Patterns of ABC use among HIV-positive paediatric patients followed national ART treatment guidelines on the application of the drug. Although ABC is commonly used in the private sector for adults, the current national ART treatment guidelines for adults and adolescents should include ABC as an alternative to standard first- or second-line ART.

The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa

AIDS ◽  
2010 ◽  
Vol 24 (6) ◽  
pp. 915-919 ◽  
Author(s):  
Lawrence Long ◽  
Matthew Fox ◽  
Ian Sanne ◽  
Sydney Rosen
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
Second Line ◽  
Second Line Antiretroviral Therapy ◽  
Hiv Aids

scholarly journals Diverse Human Immunodeficiency Virus–1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings

2019 ◽  
Vol 71 (7) ◽  
pp. e170-e177 ◽  
Author(s):  
Carole L Wallis ◽  
Michael D Hughes ◽  
Justin Ritz ◽  
Raquel Viana ◽  
Carlos Silva de Jesus ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Virologic Failure ◽  
Cd4 T Cell ◽  
Second Line ◽  
Drug Classes ◽  
Immunodeficiency Virus ◽  
Third Line ◽  
Second Line Antiretroviral Therapy

Abstract Background Human immunodeficiency virus (HIV) drug resistance profiles are needed to optimize individual patient management and to develop treatment guidelines. Resistance profiles are not well defined among individuals on failing second-line antiretroviral therapy (ART) in low- and middle-income countries (LMIC). Methods Resistance genotypes were performed during screening for enrollment into a trial of third-line ART (AIDS Clinical Trials Group protocol 5288). Prior exposure to both nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs and confirmed virologic failure on a protease inhibitor–containing regimen were required. Associations of drug resistance with sex, age, treatment history, plasma HIV RNA, nadir CD4+T-cell count, HIV subtype, and country were investigated. Results Plasma HIV genotypes were analyzed for 653 screened candidates; most had resistance (508 of 653; 78%) to 1 or more drugs. Genotypes from 133 (20%) showed resistance to at least 1 drug in a drug class, from 206 (32%) showed resistance to at least 1 drug in 2 drug classes, and from 169 (26%) showed resistance to at least 1 drug in all 3 commonly available drug classes. Susceptibility to at least 1 second-line regimen was preserved in 59%, as were susceptibility to etravirine (78%) and darunavir/ritonavir (97%). Susceptibility to a second-line regimen was significantly higher among women, younger individuals, those with higher nadir CD4+ T-cell counts, and those who had received lopinavir/ritonavir, but was lower among prior nevirapine recipients. Conclusions Highly divergent HIV drug resistance profiles were observed among candidates screened for third-line ART in LMIC, ranging from no resistance to resistance to 3 drug classes. These findings underscore the need for access to resistance testing and newer antiretrovirals for the optimal management of third-line ART in LMIC.

Sign in / Sign up

Export Citation Format

Share Document